Obtained drug clinical trial approval notice
September 25, 2025
Source: drugdu
108
On September 24, Jiudian PharmaceuticalThe company announced in the evening that it recently received the "Notice of Approval for Drug Clinical Trial" from the National Medical Products Administration (NMPA). Clinical trials will commence after completing relevant preparatory work. The relevant information is as follows: JIZM01 is indicated for closed soft tissue contusions and joint sprains, while JIZM02 is indicated for periarthritis of the shoulder. Following review, approval has been granted for clinical trials in accordance with the Drug Administration Law of the People's Republic of China and relevant regulations.
https://finance.eastmoney.com/a/202509243522589468.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
